Results 31 to 40 of about 6,174 (184)

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors : Current Status and Future Directions [PDF]

, 2015
Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability.
Bauer, Sebastian, Joensuu, Heikki
core   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Clinical proteomics for precision medicine: the bladder cancer case [PDF]

, 2017
Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of –omics based approaches.
Frantzi, Maria, Latosinska, Agnieszka, Merseburger, Axel S., Mischak, Harald, Vlahou, Antonia   +4 more
core   +1 more source

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma [PDF]

, 2022
Despite the significant progress in the treatment of unresectable or metastatic BRAF V600-mutant melanoma, there remains two primary treatment options: targeted therapy and immunotherapy.
Ascierto, Paolo A, Brill, Kimberli, Dummer, Reinhard, McKean, Meredith, Panella, Timothy, Pietro, Alessandra di, Polli, Anna, Ribas, Antoni, Robert, Caroline, Santos, Edgardo S, Schadendorf, Dirk, Sullivan, Ryan J   +11 more
core   +1 more source

MicroRNAs in melanoma development and resistance to target therapy [PDF]

, 2017
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio, Ciliberto, Gennaro, Costantini, Susan, Croce, Carlo M, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco   +7 more
core   +1 more source

Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors

Frontiers in Oncology, 2023
IntroductionCombination molecular BRAF/MEK inhibitors targeted therapy has been shown to improve overall survival in patients with BRAF V600 mutated unresectable or metastatic melanoma.
Charlotte Bonnefin, Fanny Duval, Marie Rouanet, Marie Kostine, Marie Kostine, Emilie Gerard   +5 more
doaj   +1 more source

In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor

Biomedicines, 2022
Advanced gastrointestinal stromal tumors (GIST) are typically treated with tyrosine kinase inhibitors, and imatinib is the most commonly used standard of care in first line treatments.
Patrick Schöffski, Yemarshet Gebreyohannes, Thomas Van Looy, Paul Manley, Joseph D. Growney, Matthew Squires, Agnieszka Wozniak   +6 more
doaj   +1 more source

Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition [PDF]

, 2018
Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance.
Atta, Lyla H., Claas, Allison Mary, Gordonov, Simon, Lauffenburger, Douglas A, Meyer, Aaron Samuel   +4 more
core   +1 more source

MEK inhibition and immune responses in advanced melanoma

OncoImmunology, 2017
phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma.
Reinhard Dummer, Egle Ramelyte, Sabrina Schindler, Olaf Thürigen, Mitchell P. Levesque, Peter Koelblinger   +5 more
doaj   +1 more source

Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer

Clinical and Translational Radiation Oncology, 2018
Background and purpose: In this study we have combined fractionated radiation treatment (RT) with two molecular targeted agents active against key deregulated signaling pathways in head and neck cancer.
Kevin Blas, Thomas G. Wilson, Nathan Tonlaar, Sandra Galoforo, Alaa Hana, Brian Marples, George D. Wilson   +6 more
doaj   +1 more source